---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004264"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:43:33.021494+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coherus to repurchase $170M of convertible notes, conditional on UDENYCA sale close

## Summary
- Coherus agreed to repurchase ~$170M aggregate principal of its 1.500% Convertible Notes due 2026 at 100% par plus accrued interest.
- Repurchases conditioned on closing of UDENYCA franchise divestiture to Intas Pharmaceuticals, expected early Q2 2025.
- After repurchase, ~$60M of notes remain; Coherus plans a repurchase offer for those notes post-close.
- Holders representing a majority of outstanding notes consented to indenture amendments permitting the UDENYCA divestiture.
- Amendments executed via supplemental indenture dated March 31, 2025.

## SEC filing metadata
- accession: 0001558370-25-004264
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025004264/0001558370-25-004264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025004264/chrs-20250331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004264
- JSON: https://secwatch.observer/filing/0001558370-25-004264.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004264.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.